Moringa oleifera
PreclinicalSmall molecule
Moringa oleifera is one of 68 small molecule programs targeting Postpartum Depression. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbPreclinical
Actemra
RochePreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Actos
TakedaPreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Cimzia
UCBPreclinical
Certolizumab
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postpartum Depression1 trial
Moringa Oleifera1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moringa oleifera. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversitas Sebelas Maret